Teva Pharmaceutical Industries has unveiled new real-world data showing that treatment with AUSTEDO and AUSTEDO XR significantly improves the lives of people living with Huntington’s disease (HD) chorea—and eases the burden on their caregivers.
The findings come from the first and only decentralized real-world study examining how HD chorea affects patients and caregivers and how treatment impacts quality of life.
The results paint a stark picture of the daily toll of the disease. More than two-thirds of patients reported that HD chorea interfered with their social lives and emotional wellbeing, while caregivers described widespread disruption to their own daily activities, emotional health and social functioning.
Treatment with AUSTEDO or AUSTEDO XR, however, was associated with meaningful improvements across multiple measures. Nearly three-quarters of patients reported better chorea symptoms after starting therapy, and most said those improvements translated into greater independence, stronger social engagement and better day-to-day functioning.
“What we are seeing reinforced from these real-world data is how deeply Huntington’s disease chorea affects patients – physically, emotionally and in their ability to function day-to-day – and the strain it can place on their care partners,” said Eric Hughes, Executive Vice President, Global R&D and Chief Medical Officer at Teva.
“That’s why our patient-centric approach is fundamental to our work at Teva, and why we are proud to see AUSTEDO and AUSTEDO XR delivering such meaningful improvement for patients and making a real difference in the lives of those impacted.”
The study surveyed adults living with HD chorea across the United States through the myHDstory platform, alongside caregivers supporting individuals with the condition.
Before treatment, patients reported that chorea frequently disrupted social activities, emotional wellbeing, daily routines and recreational pursuits. Caregivers described a similarly heavy burden, reporting significant effects on their own emotional health, social lives and ability to manage everyday responsibilities.
Among patients receiving AUSTEDO or AUSTEDO XR: 74% reported improvement in chorea movements after initiating treatment. More than 85% reported progress toward goals involving everyday tasks such as dressing, walking and eating. Patients also reported gains in social activities, including spending time with friends and family.
Caregivers reported benefits as well. More than three-quarters said they experienced improvements in social engagement and emotional wellbeing, including reduced stress, guilt and emotional burden as a result of reduced chorea impact on the person they care for.
“Huntington’s disease chorea extends beyond its physical symptoms, disrupting patients’ emotional wellbeing, social functioning and sense of self, while also placing immense strain on caregivers,” said Daniel Claassen, principal investigator of the study and CEO, Huntington’s Study Group.
_256_275.jpeg)
.jpeg)
